The Medicines and Healthcare products Regulatory Agency (MHRA) has issued an urgent warning to healthcare professionals and patients regarding one specific batch of Lercanidipine blood pressure tablets. This medication batch has been removed from sale immediately following a reported mix-up. The MHRA alert emphasises that this error could potentially lead to adverse side-effects for those using the affected tablets. Patients and medical providers are advised to act upon this immediate recall to ensure safety.
UK Cluster Comments